One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Restriction Endonucleases Market

[ 英語タイトル ] Restriction Endonucleases Market - Growth, Trends, and Forecast (2020 – 2025)

Product Code : MDHC0089205
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 150
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Agilent Technologies
- Thermo Fisher Scientific
- Illumina Inc.
- New England Biolabs
- Merck KGaA
- Promega Corporation
- Takara Bio Inc.

[Report Description]

The restriction endonucleases market is expected to register a CAGR of nearly 4.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the usage of restriction endonuclease enzymes in various applications, like cloning, sequencing, and restriction digestion. Furthermore, the increasing funding and investment by biotechnology and pharmaceutical companies. According to a report by Alexander Schuhmacher, Oliver Gassmann, and Markus Hinder, the pharmaceutical industry is a worldwide top investor in R&D today, and it is predicted that it will keep its role as a leading R&D stakeholder in the future, with an industry-wide forecasted total R&D spend of USD 160 billion by 2020. However, high cost of the production of restriction endonucleases is the drawback of the market growth.

Key Market Trends

Type II Segment is Dominating the Restriction Endonucleases Market

Type II restriction enzymes are the familiar ones used for everyday molecular biology applications, such as gene cloning and DNA fragmentation and analysis. These enzymes cleave DNA at fixed positions with respect to their recognition sequence, creating reproducible fragments and distinct gel electrophoresis patterns. Over 3,500 Type II enzymes have been discovered and characterized, recognizing some 350 different DNA sequences. Type II restriction endonucleases always cleave at or near their recognition sites. They produce small, well-defined fragments of DNA that help to characterize genes and genomes and that produce recombinant DNAs. As the Type II enzymes are the most used and more advantageous, the segment has the maximum share. Furthermore, the other factors propelling the segment growth are increasing investments in research and development by biotechnology and pharmaceutical companies.

North America Dominates the Market, and It is Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors, such as the presence of key players, high investments, and growing research and development programs in the field of biotechnology, pharmaceuticals in the region, and established healthcare infrastructure. Furthermore, beneficial government initiatives and increase in number of research partnerships are some of the drivers expected to increase the market growth.

Competitive Landscape

The restriction endonucleases market is moderately competitive and consists several major players. Some of the companies that are currently dominating the market are Agilent Technologies, Thermo Fisher Scientific, Illumina Inc., New England Biolabs, Merck KGaA, Promega Corporation, Takara Bio Inc., and QIAGEN NV.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Use of Restriction Endonucleases in Various Applications
4.2.2 Increasing Expenditure on Research and Development by Biotechnology and Pharmaceutical Companies.
4.3 Market Restraints
4.3.1 High Cost Restriction Endonucleases Production
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Type
5.1.1 Type I
5.1.2 Type II
5.1.3 Type III
5.1.4 Other Types
5.2 By Application
5.2.1 Genetic Engineering
5.2.2 DNA Mapping
5.2.3 Gene Sequencing
5.2.4 Other Applications
5.3 By End User
5.3.1 Pharmaceutical and Biotechnology Companies
5.3.2 Academic Research Institutes
5.3.3 Other End Users
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East & Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Agilent Technologies
6.1.2 Thermo Fisher Scientific
6.1.3 Illumina Inc.
6.1.4 New England Biolabs
6.1.5 Merck KGaA
6.1.6 Promega Corporation
6.1.7 Takara Bio Inc.




Recommended reports